A randomized, double-blind, double-dummy study comparing a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg to telmisartan 80 mg in Chinese hypertensive patients who failed to respond adequately to telmisartan 80 mg

To evaluate the efficacy and safety of a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (TH) to telmisartan 80 mg (T) in Chinese patients who failed to respond adequately to treatment with T. This is a multi-center, randomized, double-blind, double-dummy clinical...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá xīnxuèguănbìng zázhì Vol. 36; no. 4; p. 300
Main Authors Chen, Shao-xing, Zhang, Jin, Chen, Shao-liang, Chen, Jun-zhu, Yan, Xiao-wei, Ke, Yuan-nan, DU, Feng-he, Zhang, Cheng-zong, Qin, Yong-wen, Pu, Kui, Zhu, Ding-liang
Format Journal Article
LanguageChinese
Published China 01.04.2008
Subjects
Adult
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers - adverse effects
Angiotensin II Type 1 Receptor Blockers - therapeutic use
Benzimidazoles - adverse effects
Benzimidazoles - therapeutic use
Benzoates - adverse effects
Benzoates - therapeutic use
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Hydrochlorothiazide - adverse effects
Hydrochlorothiazide - therapeutic use
Hypertension - drug therapy
Male
Middle Aged
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:To evaluate the efficacy and safety of a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (TH) to telmisartan 80 mg (T) in Chinese patients who failed to respond adequately to treatment with T. This is a multi-center, randomized, double-blind, double-dummy clinical study. A total of 699 eligible hypertensive patients entered a one-week screening phase prior to the eight-week open-label T period. At the end of eight weeks, 345 patients who failed to respond to T (DBP > or = 90 mm Hg, 1 mm Hg = 0.133 kPa) were randomized to receive either TH (175 patients) or T (170 patients) for another eight weeks. Sitting and standing BP were taken 24 hours post-dose and adverse events were documented at visit with 4 weeks interval. Laboratory, ECG and physical examination were performed at screening, at baseline and at the final visit. After 8 weeks treatment, (1) The mean trough reduction in sitting diastolic blood pressure (SiDBP) from baseline in TH group was greater than that in T grou
ISSN:0253-3758